Titan Pharmaceuticals, Inc.
TTNP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.02 | -0.00 | 0.08 |
| FCF Yield | -132.39% | -114.35% | -78.09% | -19.44% |
| EV / EBITDA | -0.02 | -0.00 | -0.77 | -3.83 |
| Quality | ||||
| ROIC | -186.76% | -100.97% | -660.32% | -168.57% |
| Gross Margin | 0.00% | 100.00% | -226.67% | 86.96% |
| Cash Conversion Ratio | 0.82 | 1.27 | 0.80 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -91.31% | -76.85% | -24.96% |
| Free Cash Flow Growth | 45.31% | 13.31% | -3.29% | 55.35% |
| Safety | ||||
| Net Debt / EBITDA | 0.60 | 0.86 | 0.27 | 0.63 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 1.85 | 0.68 |
| Cash Conversion Cycle | -14,746.00 | 381,790.00 | -877.86 | -893.96 |